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STRUCTURED ABSTRACT 26 
 27 
Objective: To identify, in patients with peripheral artery disease and intermittent claudication (IC), 28 
the reproducibility of heart rate (HR), blood pressure (BP), rate pressure product (RPP), heart rate 29 
variability (HRV), and forearm and calf blood flow (BF) and vasodilatory assessments.  30 
Methods: Twenty-nine patients with IC underwent test and retest sessions, 8-12 days apart. During 31 
each session, HR, BP, HRV, BF and vasodilatory responses were measured by electrocardiogram, 32 
auscultation, spectral analysis of HRV (low frequency, LFR-R; high frequency, HFR-R) and strain 33 
gauge plethysmography (baseline BF, post-occlusion BF, post-occlusion area under the curve, 34 
AUC). Reproducibility was determined by intraclass coefficient correlation (ICC), typical error, 35 
coefficient of variation (CV) and limits of agreement.  36 
Results: The ICC for HR and BP were > 0.8 with CV < 9%. For most HRV measures, ICC were > 37 
0.9 while CV were < 7%, except for LF/HF (ICC = 0.737; CV = 93.8%). The ICC for forearm and 38 
calf baseline BF assessments were > 0.9 while CV were < 19%; variable ICC and CV for 39 
vasodilatory responses were exhibited for calf (0.653 – 0.770; 35.2 – 37.7%) and forearm (0.169 – 40 
0.265; 46.2 – 55.5%).  41 
Conclusions: In male patients with IC, systemic hemodynamic (HR and BP), cardiac autonomic 42 
modulation (LFR-R and HFR-R) and forearm and calf baseline BF assessments exhibited excellent 43 
reproducibility, whereas the level of reproducibility for vasodilatory responses were moderate to 44 
poor. Assessment reproducibility has highlighted appropriate clinical tools for the regular monitoring 45 
of disease/intervention progression in patients with IC. 46 
Key-words: peripheral artery disease; reliability; agreement; cardiovascular system; hemodynamic 47 
variables. 48 
 49 
 50 
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1. INTRODUCTION 51 
 52 
 Peripheral artery disease (PAD) affects 200 million people worldwide with this population 53 
suffering from a partial or complete artery occlusion, primarily in the lower limbs 
1
. Due to severe 54 
ischemia caused by increased oxygen demand, patients with PAD usually present with pain in the 55 
legs during walking that ceases with rest 
2, 3
; a symptom referred to as intermittent claudication (IC) 56 
4
. Patients who experience IC exhibit a reduced walking capacity and quality of life compared to the 57 
general healthy population 
5
.  58 
 Apart from limb-specific impairments, patients with IC also present with several traditional 59 
cardiovascular risk factors 
6, 7
, which contribute towards their high rates of cardiovascular events and 60 
mortality 
7, 8
. Recent studies have examined other physiological mechanisms that may be linked with 61 
the increased cardiovascular disease burden in PAD. Compared to healthy adults, augmented blood 62 
pressure (BP) 
8, 9
, decreased parasympathetic and increased sympathetic modulations to the heart 
10
 63 
as well as impairments in blood flow (BF) and vasodilation 
11
 have been reported in patients with IC. 64 
Significant associations between hemodynamic, autonomic and vascular impairments with 65 
cardiovascular disease and mortality in PAD 
12, 13
 have increased the clinical interest in evaluating 66 
these impairments to assist with early identification of increased cardiovascular risk for patients. 67 
However, the reproducibility of the tools for assessing these impairments must be confirmed before 68 
they can be consistently utilised in clinical practice. 69 
 Reproducibility is an important methodological psychometric property, especially for 70 
tracking changes over time, and crucial for identifying clinical meaningful changes for individuals 
14
. 71 
In healthy 
15, 16
 and clinical populations, such as those with hypertension 
17, 18
 and diabetes mellitus 72 
19
, electrocardiogram (ECG), auscultation, heart rate variability (HRV) and strain gauge 73 
plethysmography have been used reliably to assess heart rate (HR), BP, cardiac autonomic 74 
modulation, and BF and vasodilatory response, respectively. However, some of these measures have 75 
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been reported to be irreproducible in populations such as cardiac transplant 
20
 and chronic heart 76 
failure 
21
 patients suggesting that reproducibility may be population-specific. Furthermore, patients 77 
with IC usually present with a myriad of cardiometabolic risk factors 
6, 7
, which further aggravates 78 
hemodynamic, autonomic and vascular dysfunction 
8-11
. This particular disease presentation may 79 
lead to unique vascular and cardiac autonomic responses that may affect the reproducibility of 80 
assessments, and subsequent clinical relevance of these measures and future cardiovascular risk 81 
prediction. Currently, the reproducibility of these important prognostic assessment tools for IC 82 
patients is unknown. Thus, the aim of this study was to evaluate the reproducibility of the 83 
assessments of HR, BP, rate pressure product (RPP), HRV and upper limb and leg BF and 84 
vasodilatory responses in patients with PAD and IC. These assessment tools provide clinicians with 85 
reliable indicators for the monitoring of disease progression and cardiovascular risk in patients with 86 
IC. 87 
 88 
2. MATERIAL AND METHODS 89 
 90 
2.1. Participants 91 
 Patients with PAD and IC symptoms and enrolled in a tertiary center specialized in vascular 92 
disease were invited to participate in this study. Patients were included if they met the following 93 
criteria: (1) male; (2) aged ≥ 50 years; (3) diagnosed with Fontaine stage II of PAD 22; (4) ankle 94 
brachial index at rest ≤ 0.90 in at least 1 lower limb; (5) resting systolic and diastolic BP lower than 95 
160 and 105 mmHg, respectively; and (6) not receiving β-blockers or non-dihydropyridine calcium 96 
channel antagonists. The study’s protocol was conducted in accordance with the Declaration of 97 
Helsinki, registered with the Brazilian Clinical Trials (http://www.ensaiosclinicos.gov.br, RBR-98 
3pq58k), and approved by the Joint Committee on Ethics of Human Research of the institution 99 
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(process 667.382). Written informed consent was obtained from all patients prior to study 100 
commencement. 101 
 102 
2.2. Procedures 103 
 Figure 1 shows the timeframe of the four visits to the laboratory completed by participants 104 
during study. During the first visit, they were interviewed, and ankle brachial index, anthropometric 105 
and resting BP measures were taken. The interview identified age, the presence of cardiovascular 106 
disease and risk factors, comorbid conditions, and current medication treatment. Ankle brachial 107 
index was evaluated as previously described 
23
, and anthropometric measures of body mass and 108 
height (Welmy, 110, São Paulo, Brazil) were used to calculate body mass index (BMI). Auscultatory 109 
BP was measured in triplicate using a mercury column sphygmomanometer (Unitec, São Paulo, 110 
Brazil). Measures were taken after 5 min of rest in the seated position. During the second visit, 111 
resting BP was measured again and the mean of the 6 measures (visit 1 and 2) was defined as each 112 
participant’s resting BP. For the third and fourth visits (test and retest sessions), HR, BP, HRV, BF 113 
and vasodilatory response were measured 8-12 days apart and assessed for reproducibility. 114 
 115 
***INSERT FIGURE 1*** 116 
 117 
2.3. Experimental protocol  118 
 The participants were instructed to avoid physical exercise for the previous 48 h, caffeinated 119 
and alcoholic beverages for the previous 24 h and smoking on the day of the sessions. They were 120 
also instructed to take their medication as prescribed by their physicians. The sessions were 121 
conducted throughout the year, with some participants taken part of the study in all the year seasons. 122 
Data was collected in a temperature-controlled laboratory (21 – 22°C). 123 
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 The sessions started at 8:00 a.m and patients initially rested in the supine position for 50 min, 124 
including an initial stabilisation period of 10 min. ECG and breathing rate were recorded between 10 125 
and 20 min, while BP and HR were measured in triplicate between 20 and 25 min with the mean 126 
value used for analysis. Lower and upper limb BF and vasodilatory response were determined during 127 
the last 25 min of supine rest. 128 
 129 
2.4. Measurements 130 
 ECG (EMG System do Brazil, EMG 030110/00B, Brazil) was continuously monitored while 131 
auscultatory BP was measured in the dominant arm using a mercury sphygmomanometer (Unitec, 132 
São Paulo, Brazil). Mean BP was calculated as the sum of diastolic BP and one-third of pulse 133 
pressure (systolic – diastolic BP), while HR was recorded from the ECG immediately after BP 134 
measurement. RPP was calculated as HR x systolic BP. 135 
 For cardiac autonomic evaluation, R-R intervals from the ECG and respiratory signal from a 136 
thoracic piezoelectric belt (UFI, Pneumotrace2, California, USA) were inputted into a data 137 
acquisition system (WinDaq, DI-720, Akron, USA) at a sampling rate of 500 Hz/channel. Stationary 138 
segments (250 – 300 beats) of the HR series were assessed for HRV via spectral analysis (Heart 139 
Scope, version 1.3.0.1, New York, USA), employing an autoregressive method in accordance with 140 
Task Force recommendations 
24
. Low-frequency (LFRR) (0.04 – 0.15 Hz) and high-frequency (HFRR) 141 
(0.15 – 0.4 Hz) components of HRV were expressed in normalized units (nu) with these representing 142 
the relative contribution of each component within the total power spectrum minus the very low 143 
frequency component 
24
. Total variance (TVR-R) (0 – 0.4 Hz) and LF/HF ratio were also calculated. 144 
 Upper and lower limb BF were simultaneously determined in the dominant forearm and the 145 
leg with the lowest ankle brachial index. BF was assessed by venous occlusion plethysmography 146 
(Hokanson, AI6, Bellevue, USA), as previously described 
25
. Briefly, BF to the hand and the foot 147 
were interrupted by limb occlusion via cuffs inflated to 200 mmHg around the wrist and the ankle, 148 
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respectively. Other cuffs were placed on the upper arm and the thigh and were rapidly inflated for 10 149 
s at 40 – 60 mmHg, followed by 10 s of deflation of both cuffs. Increases in limb volumes were 150 
detected by mercury strain gauges positioned at the forearm and calf using specialised software 151 
(NIVP3; Hokanson, Bellevue, WA). Measurements were taken during 4 min (12 x 20 s cycles) and 152 
the mean was used to determine BF. Vascular resistance (VR) was determined as the ratio between 153 
mean BP and BF in each limb. Vasodilatory response to reactive hyperaemia was also assessed 
26
. 154 
After BF determination, BF to each limb was totally occluded for 5 min by inflating the thigh and 155 
arm cuffs to 200 mmHg. The cuff was then released and post-occlusion BF was measured for 4 min 156 
as described above. The vasodilatory response was calculated by: 1) the first BF measured 157 
immediately after cuff release (post-occlusion BF) and 2) the differences in area under the curve 158 
(AUC) between post- and pre-hyperaemia BF measurements. 159 
 160 
2.5. Statistical Analysis 161 
 Data normality was confirmed by Shapiro-Wilk test while the presence of heteroscedasticity 162 
was verified by significant correlations between the test-retest mean values and their absolute 163 
differences. Variables violating these assumptions were transformed via natural logarithm prior to 164 
further analysis. 165 
 Reproducibility was examined using the following parameters: 1) presence of systematic 166 
bias; 2) inter-test reliability; 3) within individual variation; and 4) bias with limits of agreement. 167 
Systematic bias was assessed as the difference between test and retest mean values using a paired t-168 
test. Inter-test reliability was evaluated by the intraclass correlation coefficient (ICC) with values < 169 
0.40 considered poor, 0.40 – 0.75 considered moderate to good, and > 0.75 considered excellent 27. 170 
Within-individual variation was evaluated by the typical error (TE) between test and retest values, 171 
expressed both in absolute and relative terms (e.g. coefficient of variation – CV) with CV < 20% 172 
considered desirable and > 30% undesirable 
28
. Lastly, agreement was evaluated by the mean bias ± 173 
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95% limits of agreement (LOA) as previously described by Bland & Altman 
29
. For the logarithm-174 
transformed data, the ratio bias */÷ 95% LOA was calculated as previously recommended 
30
. 175 
 176 
3. RESULTS 177 
 178 
 Twenty-nine male patients with IC volunteered for this study and their characteristics are 179 
summarized in Table I. In general, patients were elderly (> 60 years), had an ankle brachial index 180 
between 0.45 and 0.90 (i.e. mild to moderate PAD), presented with several cardiovascular risk 181 
factors, and were taking a range of medications such as aspirin, statins, and anti-hypertensives. 182 
 183 
***INSERT TABLE I*** 184 
 185 
 Mean values of systemic hemodynamic variables measured at test and retest, and their 186 
reproducibility indices are shown in Table II. There were no significant differences between the 187 
mean values of any variable (P > 0.05), while ICCs ranged from 0.833 (diastolic BP) to 0.908 (HR) 188 
and CVs ranged from 5.0 (mean BP) to 8.3% (RPP). For each variable, the TE and mean/ratio bias 189 
were small while the LOA varied (Table II). 190 
 191 
***INSERT TABLE II*** 192 
 193 
 Mean values of all HRV variables were not significantly different between test and retest (P > 194 
0.05, Table III) with ICCs ranging from 0.929 (ln TVR-R) to 0.986 [HFR-R (nu)], and CVs from 4.9 195 
(ln TVR-R) to 93.8% (LF/HF). For each variable, the TE and mean/ratio bias were small while the 196 
LOA varied (Table III).  197 
 198 
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***INSERT TABLE III*** 199 
 200 
 The results for BF variables are shown in Table IV. The mean values of most variables did 201 
not significantly differ between test and retest with the exception of calf BF that was significantly 202 
higher at retest (P = 0.004). Reproducibility of the forearm BF variables varied with ICCs ranging 203 
from 0.169 (post-occlusion BF) to 0.982 (BF), and CVs from 8.2 (BF) to 55.5% (post-occlusion BF). 204 
For the calf BF variables, ICCs ranged between 0.653 (AUC) to 0.928 (VR), and CVs between 17.8 205 
(VR) and 37.7% (AUC). In addition, the TE and mean bias were small while the LOA varied each 206 
forearm and calf BF variable (Table IV). 207 
 208 
***INSERT TABLE IV*** 209 
 210 
4. DISCUSSION 211 
 212 
 The main findings of this study were that in patients with PAD and IC, systemic 213 
hemodynamic, cardiac autonomic modulation and baseline BF assessments exhibited excellent 214 
reproducibility as reflected by ICC, CV and mean bias  LOA. In contrast, reproducibility of the 215 
vasodilatory response was moderate for calf and poor for forearm. These assessment tools provide 216 
clinicians with reliable indicators for the monitoring of disease progression and cardiovascular risk in 217 
PAD patients with IC. 218 
 219 
4.1. Systemic hemodynamic variables 220 
 Few studies have evaluated the reproducibility of resting BP, HR and RPP in clinical 221 
populations 
17, 31, 32
. This is surprising given the utility of these measures in guiding disease 222 
management and their positive relationship with cardiovascular morbidity and mortality 
12, 33
. 223 
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Previous studies have reported good to excellent reliability for auscultatory systolic and diastolic BP 224 
in patients with borderline hypertension (ICC: 0.61 – 0.83) 18 and untreated adults with elevated BP 225 
(ICC: 0.76 – 0.77) 17. Similarly, the current study identified excellent reproducibility (ICC > 0.80 226 
and CV < 9%) for systolic BP, diastolic BP, HR and RPP in patients with IC. These results confirm 227 
the utility of these clinical measures to assist with cardiovascular risk screening, and monitoring of 228 
disease progression and treatment in patients with PAD and IC.  229 
 230 
4.2. Cardiac autonomic modulation 231 
 HRV has been used as a non-invasive method to quantify parasympathetic and sympathetic 232 
modulations to the heart 
24
. HRV alterations, mainly characterized by decreased TVR-R and HFR-R, 233 
and increased LFR-R and LF/HF, have been reported in patients with PAD and IC compared to 234 
healthy adults 
10
 with this reduce HRV associated with greater mortality 
34
. However, to the best of 235 
our knowledge, the current study has been the first to verify the reproducibility of resting HRV in 236 
patients with IC. It is well known that reproducibility of HRV is population-specific with lower 237 
reproducibility generally obtained in clinical populations compared to healthy adults 
20, 35-37
. 238 
However, the present results showed excellent reproducibility (ICC > 0.90 and CV < 9%) for almost 239 
all indices, except for LF/HF. Previous studies of patients with a history of myocardial infarction 240 
(ICC: 0.77 – 0.81) 38 and type 2 diabetes mellitus (ICC: 0.58 – 0.71) 19 reported poor reliability for 241 
the HRV indices. In addition, the current study demonstrated good within-individual variation for 242 
TVR-R, LFR-R and HFR-R (CV < 9.0%). Previous studies have reported greater variation for these 243 
variables, even in healthy adults (CV: 20.1 – 23.0%) 39. Differences for the within-individual 244 
variation of HRV may reflect differences in resting HRV levels with healthy individuals exhibiting 245 
greater HRV compared to those with chronic diseases 
20, 35-37
. Regardless, the current study has 246 
demonstrated excellent reproducibility (i.e. excellent ICC and desirable CV) for some common HRV 247 
measures used for patients with IC. On the other hand, the LF/HF exhibited a high CV (93.8%) that 248 
11 
 
might be related to the low test and retest mean values with changes producing greater variation in 249 
the measure compared to other HRV variables. Subsequently, LF/HF should be cautiously used for 250 
the monitoring of PAD patients with IC due to its poorer reproducibility. 251 
 It is important to highlight that a range of factors may influence reproducibility (reliability 252 
and agreement) of HRV variables. Differences in internal (e.g. physiological state, mood, alertness, 253 
mental activity, etc) and external (e.g. time of day, temperature, etc) factors have been reported to 254 
influence cardiac autonomic modulation 
24, 40
, and may have an impacted on the reproducibility of 255 
test-retest measurements. A rigorous set of procedures had been implemented in the current study 256 
(e.g. control of physical activity, time of day, laboratory temperature and medication) to minimise 257 
any potential influencing factors, which may have resulted in better reproducibility indicators than 258 
that seen previously 
19, 38, 39
. Subsequently, a standardised procedure, such as that adopted in the 259 
current study, may be beneficial and vital to ensure reproducible and accurate monitoring of patients 260 
with IC. Future studies may confirm the advantages of these standardised procedures for other 261 
clinical populations. 262 
 263 
4.3. Peripheral hemodynamic variables 264 
 Patients with IC have varying degrees of arterial occlusion that consequently result in several 265 
physical limitations due to reduced BF in the limbs 
1-3
. Assessment of BF via strain gauge 266 
plethysmography has been considered the gold standard method for measure distal limb BF 
41
 with a 267 
previous study reporting similar reliability (ICC > 0.90) to that of the current study for baseline 268 
forearm and calf BFs in healthy adults 
42
. Additionally, within-individual variations for baseline 269 
forearm (8.2%) and calf BF (18.0%) were similar to those previously reported in healthy individuals 270 
42, 43
. Others 
15, 44
 though have reported higher CV for these variables with differences between 271 
studies likely a result of different populations and experimental session conditions, such as 272 
positioning of the cuff, strain gauge, assessed limb and physiological circadian rhythm. In addition, 273 
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forearm and VR also presented excellent reproducibility (ICC > 0.90 and CV < 20%) as compared 274 
with a previous study 
15
. 275 
 Considering vasodilatory response, a poor to moderate reproducibility was observed for post-276 
occlusion BF and AUC for the forearm and calf. In contrast, Altenkirch et al 
45
 and Thijssen et al 
15
 277 
reported better reproducibility via CV for forearm post-occlusion BF (10.5% and 8.6%, respectively) 278 
and calf post-occlusion BF (7.1% and 6.4%, respectively) in healthy individuals. Differences in 279 
reproducibility between studies are most likely due to the presence of vascular disease for PAD 280 
patients with post-occlusion vasodilatory responses influenced by several regulating factors (e.g. NO, 281 
prostaglandins and others) 
46
. Repeated ischemia and reperfusion during ambulation may alter these 282 
regulating factors as well as enhance oxidative stress and inflammation 
47, 48
 that contributes to the 283 
poorer reproducibility of vasodilatory response in PAD patients with IC. 284 
 285 
4.4. Practical applications  286 
 The current findings have important applications for both research and clinical settings. In 287 
general, excellent reproducibility (ICC > 0.75 and CV < 20%) was identified for systemic 288 
hemodynamics, cardiac autonomic modulation and baseline BF and VR in patients with IC that 289 
confirms their valuable and practical use to monitor disease and/or intervention progression in 290 
clinical settings. However, vasodilatory responses (i.e. post-occlusion BF and AUC) for calf (ICC > 291 
0.40 and CV > 30%) and forearm (ICC < 0.40 and CV > 30%) were moderate-poor that questions 292 
the practical relevance of these measures in patients with IC. Finally, the current study determined 293 
the specific TE for each variable that should be considered when examining smallest worthwhile 294 
changes in PAD patient’s progression and for calculating minimum sample sizes for research studies 295 
with IC patients. Moreover, the specific LOA of each variable could be employed as a cut-296 
off/minimal threshold to identify mean changes when evaluating interventions within this specific 297 
population 
49
. 298 
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4.5. Limitations 299 
 This study has some limitations, which should be acknowledged. Firstly, the current study 300 
was conducted with men only, which restricts extrapolation of the results to women. Secondly, 301 
although patients with PAD usually present other cardiovascular diseases, none of the participants of 302 
the study presented heart failure. As reproducibility parameters has been shown to be poor in heart 303 
failure 
21
, results might be different in patients with this comorbidity. Third, different medications 304 
might affect cardiovascular reproducibility. The current study included medication regimes typically 305 
used in patients with PAD excepted for β-blockers and non-dihydropyridine calcium channel 306 
antagonists because these drugs directly affect the assessment of heart rate variability. Therefore, the 307 
results were not applicable to patients receiving these specific drugs. Finally, as seasonal variations 308 
may impact on cardiovascular parameters and test and retest had been conducted at the same season 309 
of the year, the reproducibility indices obtained in the current study are valid for within season 310 
measures but may be different if test and retest were conducted at different seasons. The limitations 311 
of the present study suggest that future study should investigate the reproducibility indices in patients 312 
with PAD who are women, have heart failure, and are receiving β-blockers or non-dihydropyridine 313 
calcium channel antagonists. In addition, future studies should address reproducibility between 314 
different seasons of the year. 315 
 316 
5. CONCLUSIONS  317 
 318 
 Systemic hemodynamic (HR and auscultatory BP), cardiac autonomic modulation (TVR-R, 319 
LFR-R and HFR-R) and baseline BF assessments exhibited excellent reproducibility at rest for male 320 
patients with IC with these tools highly appropriate for clinical monitoring of patients. However, the 321 
level of reproducibility for vasodilatory responses (post-occlusion BF and AUC) of the calf and 322 
14 
 
forearm was moderate to poor that highlighted the limitations of these tools for regular monitoring of 323 
disease/intervention in PAD patients. 324 
 325 
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LEGENDS TO ILLUSTRATION 460 
 461 
Figure 1. Timeframe of the 4 visits. BMI – Body Mass Index; ABI – Ankle Brachial Index; BP 462 
– Blood Pressure; HR – Heart Rate; HRV – Heart Rate Variability; BF – Blood Flow. 463 
 464 
 
 
 
Table I. Clinical characteristics of patients 
n 29
 
Age, y 67 ± 11 
Height, m 1.67 ± 0.07 
Weight, kg 71.0 ± 10.1 
Body mass index, kg/m
2
 25.3 ± 3.3 
Ankle brachial index 0.62 ± 0.13 
Cardiovascular measures  
Systolic blood pressure (mmHg) 136 ± 15 
Diastolic blood pressure (mmHg) 82 ± 9 
Heart rate (bpm) 72 ± 11 
Cardiovascular risk factors and comorbidities  
Obesity, %
 
6.9 
Hypertension, %
 
69.0 
Diabetes mellitus, %
 
27.6 
Dyslipidaemia, %
 
93.1 
Current smoker, % 34.5 
Heart disease, % 17.2 
Medications  
Aspirin, % 93.1 
Statin, % 93.1 
Angiotensin-converting enzyme inhibitor, % 44.8 
Diuretic, % 24.1 
Dihydropyridine calcium channel antagonist, % 20.7 
Table
 
 
 
Oral hypoglycaemic, % 27.6 
Continuous data are expressed as mean ± SD. Categorical data are expressed as percentage of 
occurrence (%). Obesity was defined as body mass index ≥ 30 kg/m. Hypertension, diabetes 
mellitus, dyslipidaemia and heart disease were defined by previous physician diagnosis. 
 
 
 
Table II. Mean ± SD values and reproducibility parameters of systemic hemodynamic variables 
 Test Retest  P value ICC TE  CV % Bias ± 95%LOA 
Systolic BP (mmHg) 134 ± 13 132 ± 16 0.409 0.863 7.2 5.4 1.6 ± 20.0 
Diastolic BP (mmHg) 78 ± 8 77 ± 9 0.362 0.833 4.8 6.2 1.1 ± 13.2 
Mean BP (mmHg) 96 ± 9 95 ± 10 0.306 0.845 4.8 5.0 1.3 ± 13.2 
HR (bpm) 66.6 ± 9.1 64.6 ± 8.8 0.062 0.908 3.7 5.6 2.0 ± 10.2 
RPP (mmHg.bpm) 8879 ± 1347 8494 ± 1520 0.060 0.856 720 8.3 385 ± 1994 
BP – blood pressure; HR – heart rate; RPP – rate pressure product; ICC – intraclass correlation coefficient; TE – typical error; CV – coefficient 
of variation; LOA – limits of agreement 
Table
 
 
 
Table III. Mean ± SD values and reproducibility parameters of autonomic variables 
 Test Retest  P value ICC TE CV % Bias ± or */÷ 95% LOA 
ln TVR-R (ms
2
) 6.8 ± 1.0 6.9 ± 0.9 0.459 0.929 0.3 4.9 0.9 */÷ 2.6 
LFR-R (nu) 47.8 ± 19.9 47.5 ± 18.8 0.831 0.979 4.0 8.3 0.3 ± 11.0 
HFR-R (nu) 44.7 ± 20.7 45.5 ± 19.4 0.535 0.986 3.3 7.3 -0.7 ± 9.1 
ln LF/HF 0.18 ± 0.87 0.17 ± 0.88 0.737 0.982 0.16 93.8 1.0 */÷ 1.6 
ln – natural logarithm; TV – total variance; LF – low frequency component; HF – high frequency component; nu – normalized units; ICC – 
intraclass correlation coefficient; TE – typical error; CV – coefficient of variation; LOA – limits of agreement 
 
Table
 
 
 
Table IV. Mean ± SD values and reproducibility forearm and calf blood flows and vasodilatory response variables  
 Test Retest  P value ICC TE CV % Bias ± 95% LOA 
Forearm         
BF (ml.100 ml
-1
.min
-1
) 1.42 ± 0.63 1.41 ± 0.59 0.872 0.982 0.12 8.2 0.00 ± 0.32 
VR (U) 75 ± 35 74 ± 32 0.627 0.978 7.0 9.3 1 ± 19 
Post-occlusion BF (ml.100 ml
-1
.min
-1
) 11.4 ± 7.0 11.2 ± 6.1 0.938 0.169 6.3 55.5 0.15 ± 17.37 
Post-occlusion AUC BF (U) 1294 ± 676 1085 ± 507 0.232 0.265 550 46.2 209 ± 1524 
Calf        
BF (ml.100 ml
-1
.min
-1
) 1.69 ± 0.72 2.06 ± 0.95 0.004 0.913 0.34 18.0 -0.37 ± 0.94 
VR (U) 60 ± 25 57 ± 31 0.362 0.928 10.0 17.8 3 ± 29 
Post-occlusion BF (ml.100 ml
-1
.min
-1
) 5.73 ± 3.18 5.05 ± 3.04 0.297 0.770 1.9 35.2 0.68 ± 5.27 
Post-occlusion AUC BF (U) 999 ± 467 1081 ± 616 0.553 0.653 392 37.7 -82 ± 1088 
BF – blood flow; VR – vascular resistance; AUC – area under the curve; ICC – intraclass correlation coefficient; TE – typical error; CV – 
coefficient of variation; LOA – limits of agreement. 
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